E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
myelofibrosis |
mielofibrosi |
|
E.1.1.1 | Medical condition in easily understood language |
myelofibrosis |
mielofibrosi |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10028537 |
E.1.2 | Term | Myelofibrosis |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate and compare the efficacy of parsaclisib plus ruxolitinib versus placebo plus ruxolitinib on spleen volume at Week 24. |
Valutare e confrontare l’efficacia di parsaclisib più ruxolitinib rispetto a placebo più ruxolitinib sul volume della milza alla Settimana 24 |
|
E.2.2 | Secondary objectives of the trial |
* To evaluate and compare the effect of parsaclisib plus ruxolitinib versus placebo plus ruxolitinib on participant reports of MF symptoms. * To evaluate and compare the effect of parsaclisib plus ruxolitinib versus placebo plus ruxolitinib with respect to OS. * To evaluate and compare the safety and tolerability of parsaclisib plus ruxolitinib versus placebo plus ruxolitinib |
* Valutare e confrontare l’effetto di parsaclisib più ruxolitinib rispetto a placebo più ruxolitinib sui sintomi di MF riferiti dai partecipanti. * Valutare e confrontare l’effetto di parsaclisib più ruxolitinib rispetto a placebo più ruxolitinib in termini di OS. * Valutare e confrontare la sicurezza e la tollerabilità di parsaclisib più ruxolitinib rispetto a placebo più ruxolitinib. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Men and women aged 18 years or older; 2. Diagnosis of PMF, PPV-MF, or PET-MF; 3. DIPSS risk category of intermediate-1, intermediate-2, or high; 4. Treated with ruxolitinib for = 3 months with a stable dose for at least the last 8 weeks prior to Day 1; 5. Evidence of suboptimal response to ruxolitinib For the complete list of inclusion criteria please refer to the protocol, section 5.1 |
1. Uomini e donne di età pari o superiore a 18 anni; 2. Diagnosi di PMF, PPV-MF o PET-MF; 3. Categoria di rischio DIPSS intermedio-1, intermedio-2 o alto; 4. Trattato con ruxolitinib per = 3 mesi con una dose stabile per almeno le ultime 8 settimane prima del giorno 1; 5. Evidenza di una risposta non ottimale a ruxolitinib Per l'elenco completo dei criteri di inclusione, fare riferimento al protocollo, sezione 5.1 |
|
E.4 | Principal exclusion criteria |
1. Prior therapy with any drug that inhibits PI3K; 2. Use of experimental drug therapy for MF or any other standard drug used for MF (e.g., danazol, hydroxyurea) with the exception of ruxolitinib, within 3 months of starting study drug, and/or lack of recovery from all toxicities from previous therapy (except ruxolitinib) to Grade 1 or better. 3. Inability to swallow food or any condition of the upper gastrointestinal tract that precludes administration of oral medications. 4. Recent history of inadequate bone marrow reserve. For the complete list of exclusion criteria please refer to the protocol, section 5.2 |
1. Terapia precedente con qualsiasi farmaco che inibisce PI3K; 2. Uso della terapia farmacologica sperimentale per la MF o di qualsiasi altro farmaco standard usato per la MF (ad es. Danazolo, idrossiurea) ad eccezione di ruxolitinib, entro 3 mesi dall'inizio del farmaco in studio e / o mancanza di recupero da tutte le tossicità dalla terapia precedente (eccetto ruxolitinib) al Grado 1 o migliore. 3. Incapacità di deglutire il cibo o qualsiasi condizione del tratto gastrointestinale superiore che precluda la somministrazione di farmaci per via orale. 4. Storia recente di riserva di midollo osseo inadeguata. Per l'elenco completo dei criteri di esclusione fare riferimento al protocollo, sezione 5.2 |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of participants achieving >= 25% reduction in spleen volume from baseline to Week 24 as measured by MRI (or CT scan in applicable participants). |
Percentuale di partecipanti che ottengono una riduzione >=25% del volume della milza dal basale alla Settimana 24 misurata mediante RM (o TAC laddove pertinente). |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
* Proportion of participants who have a >= 50% reduction in TSS from baseline to Week 24 as measured by the MFSAF v4.0 diary * Change in TSS from baseline to Week 24 as measured by the MFSAF v4.0 diary. * Time to the first >= 50% reduction in TSS as measured by the MFSAF v4.0 diary * OS determined from the date of randomization until death due to any cause. * Safety and tolerability |
Percentuale di partecipanti che presentano una riduzione =50% dal basale alla Settimana 24 misurata dal diario MFSAF v4.0. Cambiamento nel TSS dal basale alla Settimana 24 misurato dal diario MFSAF v4.0. Tempo alla prima riduzione >=50% nel TSS misurato dal diario MFSAF v4.0. L’OS sarà determinata dalla data di randomizzazione fino alla data di decesso per qualunque causa. La sicurezza e la tollerabilità saranno valutate mediante monitoraggio della frequenza e della gravità degli AE, eseguendo esami obiettivi e valutando i cambiamenti nei parametri vitali, negli ECG e nei risultati di laboratorio. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
* Proportion of participants with >= 50% reduction in TSS: week 24 * Change in TSS: week 24 * Time to the first >= 50% reduction in TSS: * OS: throughout the study * Safety and tolerability: throughout the study |
* Proporzione di partecipanti con riduzione = 50% del TSS: settimana 24 * Modifica del TSS: settimana 24 * Tempo alla prima riduzione >= 50% del TSS: * OS: durante lo studio * Sicurezza e tollerabilità: durante tutto lo studio |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 16 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 70 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Canada |
China |
Japan |
United States |
Austria |
Belgium |
Finland |
France |
Germany |
Hungary |
Ireland |
Italy |
Norway |
Poland |
Spain |
United Kingdom |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |